<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01810991</url>
  </required_header>
  <id_info>
    <org_study_id>CYN12-1440-BK-HID1</org_study_id>
    <nct_id>NCT01810991</nct_id>
  </id_info>
  <brief_title>Investigation of Hyperhidrosis Treatment Using the Nd: YAG 1440nm Wavelength Laser</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm&#xD;
      wavelength laser for the treatment of primary hyperhidrosis of the axilla.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Photographs Identified Accurately</measure>
    <time_frame>3 Month Follow Up</time_frame>
    <description>3 trained blinded evaluators were asked to pick the post treatment photo from pre and post treatment photograph sets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Photographs Identified Accurately</measure>
    <time_frame>6 Month Follow Up</time_frame>
    <description>3 trained blinded evaluators were asked to pick the post treatment photo from pre and post treatment photograph sets.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Changed and Unchanged Glands on Biopsy Sampling</measure>
    <time_frame>up to 3 months post last treatment</time_frame>
    <description>Hematoxylin and eosin (H&amp;E) staining was performed on all pre and post treatment biopsy samples and evaluated by a pathologist to determine if there was any change in the subjects' glands at baseline vs. post last treatment. Changes in glands are characterized by reduction in quantity and size, in addition to changes in shape.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>HYPERHIDROSIS</condition>
  <arm_group>
    <arm_group_label>Nd:YAG Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nd:YAG 1440nm Laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nd:YAG Laser</intervention_name>
    <description>Nd:YAG 1440nm Laser</description>
    <arm_group_label>Nd:YAG Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A healthy non-smoking male or female between 18-56 years of age&#xD;
&#xD;
          -  Understand/accept obligation not to receive any other procedures in anatomical areas&#xD;
             exhibiting axillary hyperhidrosis through 3 months prior to treatment&#xD;
&#xD;
          -  Understand and accept the obligation and is logistically able to present for all&#xD;
             scheduled follow-up visits&#xD;
&#xD;
          -  Clinically diagnosed for primary hyperhidrosis of the axilla.&#xD;
&#xD;
          -  A self assessed Hyperhidrosis Disease Severity Scale (HDSS) score of three (3) or four&#xD;
             (4)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of secondary hyperhidrosis&#xD;
&#xD;
          -  Uncontrolled systemic disease&#xD;
&#xD;
          -  Concurrent use of any hyperhidrosis treatments other than over the counter&#xD;
             antiperspirants or deodorants&#xD;
&#xD;
          -  Receipt of Botox or Dysport within the past six months&#xD;
&#xD;
          -  Patients who refuse to stop using over the counter antiperspirants 24 hours prior to&#xD;
             the day of surgery and each of the follow-up visits at 3 months and 6 months that&#xD;
             Minors starch iodine tests may be performed.&#xD;
&#xD;
          -  Patients using or having used within 7 days of baseline visit: cholinomimetic agents,&#xD;
             anticholinergic agents, prescription antiperspirants, any herbal medicine treatments&#xD;
             or any other treatments for hyperhidrosis except over the counter antiperspirant or&#xD;
             planning to use such agents during the course of the study.&#xD;
&#xD;
          -  Any previous liposuction/liposculpture or any type of surgery for hyperhidrosis; OR&#xD;
             any other types of treatments for hyperhidrosis in the area to be treated in the past&#xD;
             6 months or planning to have any treatments for hyperhidrosis or surgery within the&#xD;
             treatment area during the course of the study.&#xD;
&#xD;
          -  Allergies to medication or local anesthesia required for the procedure&#xD;
&#xD;
          -  A history of thrombophlebitis&#xD;
&#xD;
          -  A history of acute infections&#xD;
&#xD;
          -  A history of heart failure&#xD;
&#xD;
          -  Received or is anticipated to receive antiplatelets, anticoagulants, thrombolytics,&#xD;
             vitamin E or anti inflammatories within 2 weeks pre treatment&#xD;
&#xD;
          -  An intolerance to anesthesia&#xD;
&#xD;
          -  Any medical condition, that, in the investigator's opinion would interfere with the&#xD;
             patient's participation in the study&#xD;
&#xD;
          -  Taking medications that are photosensitive&#xD;
&#xD;
          -  A history of keloid formation&#xD;
&#xD;
          -  Is pregnant or has been pregnant in the last 3 months, currently breast feeding or&#xD;
             planning a pregnancy during the course of the study&#xD;
&#xD;
          -  Study subjects that can not maintain their pre-study exercise and diet routine over&#xD;
             the course of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juva Skin and Laser Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2013</study_first_posted>
  <results_first_submitted>October 15, 2020</results_first_submitted>
  <results_first_submitted_qc>November 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2020</results_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nd:YAG Laser</title>
          <description>Nd:YAG 1440nm Laser&#xD;
Nd:YAG Multiwavelength Diode Laser Using 1440nm Wavelength. A Rep Rate of 25 Hz was used.&#xD;
Each subject received 1 treatment using this laser.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nd:YAG Laser</title>
          <description>Nd:YAG 1440nm Laser&#xD;
Nd:YAG Laser: Nd:YAG 1440nm Laser</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American/Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Score</title>
          <description>The Fitzpatrick Skin Score is used to determine skin color. It is a numerical system that classifies skin into six types (Type I, Type II, Type III, Type IV, Type V and Type VI) based on the numerical score achieved (ranging from 0 to 36). The lower the score (and skin type number), the fairer the skin. The higher the score (and skin type number), the more deeply pigmented the skin is.&#xD;
The scale comes from this source:&#xD;
Gupta, Sharma. Skin typing: Fitzpatrick grading and others. Clinics in Dermatology. 2019;37(5):430-436. doi:10.1016/j.clindermatol.2019.07.010</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Fitzpatrick Skin Type I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Type II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Type III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Type IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Type V</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Type VI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Photographs Identified Accurately</title>
        <description>3 trained blinded evaluators were asked to pick the post treatment photo from pre and post treatment photograph sets.</description>
        <time_frame>3 Month Follow Up</time_frame>
        <population>The subject was lost to follow up (not due to adverse events).</population>
        <group_list>
          <group group_id="O1">
            <title>Nd:YAG Laser</title>
            <description>Nd:YAG 1440nm Laser&#xD;
Nd:YAG Laser: Nd:YAG 1440nm Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Photographs Identified Accurately</title>
          <description>3 trained blinded evaluators were asked to pick the post treatment photo from pre and post treatment photograph sets.</description>
          <population>The subject was lost to follow up (not due to adverse events).</population>
          <units>% of photographs identified correctly</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Photographs Identified Accurately</title>
        <description>3 trained blinded evaluators were asked to pick the post treatment photo from pre and post treatment photograph sets.</description>
        <time_frame>6 Month Follow Up</time_frame>
        <population>Anything beyond the 3 month follow up was not required, and the subject chose not to come in.</population>
        <group_list>
          <group group_id="O1">
            <title>Nd:YAG Laser</title>
            <description>Nd:YAG 1440nm Laser&#xD;
Nd:YAG Laser: Nd:YAG 1440nm Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Photographs Identified Accurately</title>
          <description>3 trained blinded evaluators were asked to pick the post treatment photo from pre and post treatment photograph sets.</description>
          <population>Anything beyond the 3 month follow up was not required, and the subject chose not to come in.</population>
          <units>% of photographs identified correctly</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Changed and Unchanged Glands on Biopsy Sampling</title>
        <description>Hematoxylin and eosin (H&amp;E) staining was performed on all pre and post treatment biopsy samples and evaluated by a pathologist to determine if there was any change in the subjects' glands at baseline vs. post last treatment. Changes in glands are characterized by reduction in quantity and size, in addition to changes in shape.</description>
        <time_frame>up to 3 months post last treatment</time_frame>
        <population>The biopsy portion of the study was optional, so there were only 5 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Nd:YAG Laser</title>
            <description>Nd:YAG 1440nm Laser&#xD;
Nd:YAG Laser: Nd:YAG 1440nm Laser</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changed and Unchanged Glands on Biopsy Sampling</title>
          <description>Hematoxylin and eosin (H&amp;E) staining was performed on all pre and post treatment biopsy samples and evaluated by a pathologist to determine if there was any change in the subjects' glands at baseline vs. post last treatment. Changes in glands are characterized by reduction in quantity and size, in addition to changes in shape.</description>
          <population>The biopsy portion of the study was optional, so there were only 5 subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title># of Participants with Only Unchanged Glands</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title># of Participants with Changed Glands</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the study duration, around 12 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nd:YAG Laser</title>
          <description>Nd:YAG 1440nm Laser&#xD;
Nd:YAG Laser: Nd:YAG 1440nm Laser</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hardness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jamie Trimper</name_or_title>
      <organization>Cynosure</organization>
      <phone>800-886-2966</phone>
      <email>jamie.trimper@cynosure.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

